Shimadzu UK Appoints Product Specialist for AA
News Jul 19, 2012
Shimadzu UK Ltd is continuing the company’s programme of investment in the molecular and atomic spectroscopy markets by appointing Andy Winn as a Product Specialist for atomic absorption (AA), inductively coupled plasma (ICP) and total organic carbon (TOC) in Shimadzu UK’s Spectroscopy Group.
Winn, who has an enviable reputation for developing close customer relationships across the spectroscopy market, was formerly with Thermo Fisher Scientific before moving to Varian UK Ltd and Agilent Technologies.
Winn, who brings a wealth of knowledge of AA and ICP techniques, joins Shimadzu at a time of strong growth across all the company’s spectroscopy products.
Winn’s appointment will help Shimadzu UK Ltd to continue to strengthen its position in the UK atomic spectroscopy sector at a time when Shimadzu has created a collaborative agreement with the Civil Engineering department of Loughborough University for ICP applications in environmental and building applications.
“This is an exciting time to join Shimadzu’s Spectroscopy Group because the company is busy creating new benchmarks in atomic and molecular spectroscopy,” explained Winn.
“For example, Shimadzu’s breakthrough Lo-Ray-Ligh diffraction grating technology is now installed in Shimadzu’s new UV-2600 and UV-2700 model UV spectrophotometers which not only increases the linear absorbance range of these instruments to unprecedented levels, but also extends the wavelength range of these instruments to enable analysis in the near infra-red region”.
Compact Chemical Sensor Can Detect Substances from Over 100 Feet AwayNews
A chemical sensor prototype developed at the University of Michigan will be able to detect "single-fingerprint quantities" of substances from a distance of more than 100 feet away, and its developers are working to shrink it to the size of a shoe box. The development offers great potential for medical and law enforcement purposes.READ MORE
Multidisciplinary Study Suggests New Strategy for Drug DiscoveryNews
A joint industry/academia study of a cancer target protein reveals unusual relation between binding site flexibility and drug-target lifetime. The results, , suggest a new strategy for drug discovery.READ MORE